Targeted Drugs and Nanomedicine: Present and Future
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Packaging small-molecule drugs into nanoparticles improves their bio-availability, bio-compatibility and safety profiles. Multifunctional particles carrying large drug payloads for targeted transport, immune evasion and favourable drug release kinetics at the target site, require a certain minimum size usually 30-300 nm diameter, so are nanoparticles. Targeting particles to a disease site can signal the presence of the disease site, block a function there, or deliver a drug to it. Targeted nanocarriers must navigate through blood-tissue barriers, varying in strength between organs and highest in the brain, to reach target cells. They must enter target cells to contact cytoplasmic targets; specific endocytotic and transcytotic transport mechanisms can be used as trojan horses to ferry nanoparticles across cellular barriers. Specific ligands to cell surface receptors, antibodies and antibody fragments, and aptamers can all access such transport mechanisms to ferry nanoparticles to their targets. The pharmacokinetics and pharmacodynamics of the targeted drug-bearing particle depend critically on particle size, chemistry, surface charge and other parameters. Particle types for targeting include liposomes, polymer and protein nanoparticles, dendrimers, carbon-based nanoparticles e.g. fullerenes, and others. Immunotargeting by use of monoclonal antibodies, chimeric antibodies and humanized antibodies has now reached the stage of clinical application. High-quality targeting groups are emerging: antibody engineering enables generation of human/like antibody (fragments) and facilitates the search for clinically relevant biomarkers; conjugation of nanocarriers to specific ligands and to aptamers enables specific targeting with improved clinical efficacy. Future developments depend on identification of clinically relevant targets and on raising targeting efficiency of the multifunctional nanocarriers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles
Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7339 · Cited by 7,891
Passage of inhaled particles into the blood circulation in humans
Nemmar, A., Hoet, P. H. M., Vanquickenborne, B., Dinsdale, D., Thomeer, M., Hoylaerts, M. F., Vanbilloen, H., Mortelmans, L., & Nemery, B. (2002) · Circulation · doi:10.1161/hc0402.104118 · Cited by 1,719
Donaldson, K., Aitken, R., Tran, L., Stone, V., Duffin, R., Forrest, G., & Alexander, A. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj130 · Cited by 1,167 · cited 3×
“This has been best studied for inhalation toxicity [286], confirming the potentiating effects of surface area [24].”
BackgroundNanoparticle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency
Jani, P., Halbert, G. W., Langridge, J., & Florence, A. T. (1990) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1990.tb07033.x · Cited by 920 · cited 2×
“Those targeted payloads which pass through the mucus and then through the underlying enterocyte layer can enter a nanoparticle size-dependent systemic distribution via the lymphatics [36].”
BackgroundApolipoprotein E: Structure-Function Relationships
Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830
Transcytosis: Crossing Cellular Barriers
TUMA, P. L., & HUBBARD, A. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00001.2003 · Cited by 681 · cited 1×
“This leads to uptake via active endocytosis [101-107].”
BackgroundDelivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679
Activation of Hepatic Stem Cell Marker EpCAM by Wnt–β-Catenin Signaling in Hepatocellular Carcinoma
Yamashita, T., Budhu, A., Forgues, M., & Wang, X. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0908 · Cited by 446
Rajasekaran, S. A., Anilkumar, G., Oshima, E., Bowie, J. U., Liu, H., Heston, W., Bander, N. H., & Rajasekaran, A. K. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-11-0731 · Cited by 226 · cited 1×
“However, like other barriers in the body, it contains specific portals of entry and exit; several molecular motifs have been identified, such as filamin A [14] and the MXXXL cytoplasmic tail motif of the prostate specific membrane antigen PSMA [15], which mediate and regulate internalization of proteins into the cell…”
Background
Cited by
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
Perry, J. L., Reuter, K. G., Kai, M. P., Herlihy, K. P., Jones, S. W., Luft, J. C., Napier, M., Bear, J. E., & DeSimone, J. M. (2012) · Nano Letters · doi:10.1021/nl302638g · Cited by 606
Polymeric Conjugates for Drug Delivery
Larson, N., & Ghandehari, H. (2012) · Chemistry of Materials · doi:10.1021/cm2031569 · Cited by 580
Zhang, X., Meng, L., Lu, Q., Fei, Z., & Dyson, P. J. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.025 · Cited by 536
Nanoparticles: Taking a Unique Position in Medicine
Joseph, T., Kar Mahapatra, D., Esmaeili, A., Piszczyk, Ł., Hasanin, M., Kattali, M., Haponiuk, J., & Thomas, S. (2023) · Nanomaterials · doi:10.3390/nano13030574 · Cited by 480
Metadata
- Authors
- Debbage, P.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-01-01
- Volume
- 15
- Issue
- 2
- Pages
- 153-172
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W1968970438
- Cited by
- 213
- References
- 9
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.